Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19

DOI record: { "DOI": "10.1007/s40121-024-01031-z", "ISSN": [ "2193-8229", "2193-6382" ], "URL": "http://dx.doi.org/10.1007/s40121-024-01031-z", "alternative-id": [ "1031" ], "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "13 May 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "5 August 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "4 September 2024" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Conflict of Interest", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "Dipak R. Patel, Lisa Macpherson, Martin Bohm, Carmen Deveau, Paul Klekotka, Mark Williams, and Matthew M. Hufford are employees and/or stockholders of Eli Lilly and Company. Himanshu Upadhyaya was an employee at Eli Lilly and Company at the time of study and development of the manuscript and is currently employed by Supernus Pharmaceuticals, Inc. Rockville, Maryland, USA. Ajay Nirula was an employee at Eli Lilly and Company at the time of study and development of the manuscript and is currently employed by Recludix Pharma, San Diego, California, USA." }, { "group": { "label": "Ethics Approval and Consent to Participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "The study was conducted in accordance with the principles of the Declaration of Helsinki (2000), the International Conference on Harmonization, and the E6 Guideline for Good Clinical Practice. Institutional review board approval and written informed consent from all subjects were obtained before the conduct of any evaluations or study procedures." }, { "group": { "label": "Consent for Publication", "name": "EthicsHeading" }, "name": "Ethics", "order": 4, "value": "All authors have given their consent and approval of the final version to be submitted and published." } ], "author": [ { "affiliation": [], "family": "Patel", "given": "Dipak R.", "sequence": "first" }, { "affiliation": [], "family": "Macpherson", "given": "Lisa", "sequence": "additional" }, { "affiliation": [], "family": "Bohm", "given": "Martin", "sequence": "additional" }, { "affiliation": [], "family": "Upadhyaya", "given": "Himanshu", "sequence": "additional" }, { "affiliation": [], "family": "Deveau", "given": "Carmen", "sequence": "additional" }, { "affiliation": [], "family": "Nirula", "given": "Ajay", "sequence": "additional" }, { "affiliation": [], "family": "Klekotka", "given": "Paul", "sequence": "additional" }, { "affiliation": [], "family": "Williams", "given": "Mark", "sequence": "additional" }, { "affiliation": [], "family": "Hufford", "given": "Matthew M.", "sequence": "additional" } ], "container-title": "Infectious Diseases and Therapy", "container-title-short": "Infect Dis Ther", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2024, 9, 4 ] ], "date-time": "2024-09-04T15:02:11Z", "timestamp": 1725462131000 }, "deposited": { "date-parts": [ [ 2024, 9, 4 ] ], "date-time": "2024-09-04T15:03:44Z", "timestamp": 1725462224000 }, "funder": [ { "DOI": "10.13039/100004312", "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/100004312", "id-type": "DOI" } ], "name": "Eli Lilly and Company" } ], "indexed": { "date-parts": [ [ 2024, 9, 5 ] ], "date-time": "2024-09-05T00:39:25Z", "timestamp": 1725496765079 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 9, 4 ] ] }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 9, 4 ] ], "date-time": "2024-09-04T00:00:00Z", "timestamp": 1725408000000 } }, { "URL": "https://creativecommons.org/licenses/by-nc/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 9, 4 ] ], "date-time": "2024-09-04T00:00:00Z", "timestamp": 1725408000000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-024-01031-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1007/s40121-024-01031-z/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1007/s40121-024-01031-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1007", "published": { "date-parts": [ [ 2024, 9, 4 ] ] }, "published-online": { "date-parts": [ [ 2024, 9, 4 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "key": "1031_CR1", "unstructured": "COVID-19 Treatment Guidelines. National Institute of Health. Available: https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/. Accessed 31 Mar 2022." }, { "DOI": "10.1126/science.abb2762", "author": "R Yan", "doi-asserted-by": "publisher", "first-page": "1444", "journal-title": "Science", "key": "1031_CR2", "unstructured": "Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–8.", "volume": "367", "year": "2020" }, { "author": "Q Wang", "issue": "894–904", "journal-title": "Cell", "key": "1031_CR3", "unstructured": "Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(894–904):e9.", "volume": "181", "year": "2020" }, { "DOI": "10.1038/nature02145", "author": "W Li", "doi-asserted-by": "publisher", "first-page": "450", "journal-title": "Nature", "key": "1031_CR4", "unstructured": "Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4.", "volume": "426", "year": "2003" }, { "DOI": "10.1038/s41586-020-2772-0", "author": "DJ Benton", "doi-asserted-by": "publisher", "first-page": "327", "journal-title": "Nature", "key": "1031_CR5", "unstructured": "Benton DJ, Wrobel AG, Xu P, et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature. 2020;588:327–30.", "volume": "588", "year": "2020" }, { "key": "1031_CR6", "unstructured": "Bamlanivimab/Etesevimab. 2023. Available https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Bamlanivimab-etesevimab/Pages/default.aspx. Accessed 22 Apr 2024." }, { "key": "1031_CR7", "unstructured": "Fact sheet for health care providers Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. Food and Drug Administration, 2021. Available: https://www.fda.gov/media/145802/download. Accessed 22 Feb 2022." }, { "DOI": "10.1056/NEJMoa2102685", "author": "M Dougan", "doi-asserted-by": "publisher", "first-page": "1382", "journal-title": "N Engl J Med", "key": "1031_CR8", "unstructured": "Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385:1382–92.", "volume": "385", "year": "2021" }, { "DOI": "10.1093/cid/ciab912", "author": "M Dougan", "doi-asserted-by": "publisher", "first-page": "e440", "journal-title": "Clin Infect Dis", "key": "1031_CR9", "unstructured": "Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. 2021;75:e440–9.", "volume": "75", "year": "2021" }, { "DOI": "10.1001/jama.2022.1243", "author": "CL Behr", "doi-asserted-by": "publisher", "first-page": "980", "journal-title": "JAMA", "key": "1031_CR10", "unstructured": "Behr CL, Joynt Maddox KE, Meara E, Epstein AM, Orav EJ, Barnett ML. Anti-SARS-CoV-2 monoclonal antibody distribution to high-risk Medicare beneficiaries, 2020–2021. JAMA. 2022;327:980–3.", "volume": "327", "year": "2022" }, { "DOI": "10.1007/s40121-024-00918-1", "author": "RM Nichols", "doi-asserted-by": "publisher", "first-page": "401", "issue": "2", "journal-title": "Infect Dis Ther", "key": "1031_CR11", "unstructured": "Nichols RM, Macpherson L, Patel DR, Yeh WW, Peppercorn A. Effect of bamlanivimab as monotherapy or in combination with etesevimab or sotrovimab on persistently high viral load in patients with mild-to-moderate COVID-19: a randomized, phase 2 BLAZE-4 trial. Infect Dis Ther. 2024;13(2):401–11.", "volume": "13", "year": "2024" }, { "key": "1031_CR12", "unstructured": "IV PUSH VS IV INFUSION: WHICH ONE’S BETTER? 2017. Available: https://www.vitamininjections.co.uk/iv-push-vs-iv-infusion-which-is-better/. Accessed 7 Feb 2024." }, { "DOI": "10.1001/jama.2021.0202", "author": "RL Gottlieb", "doi-asserted-by": "publisher", "first-page": "632", "issue": "7", "journal-title": "JAMA", "key": "1031_CR13", "unstructured": "Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–44. https://doi.org/10.1001/jama.2021.0202", "volume": "325", "year": "2021" }, { "key": "1031_CR14", "unstructured": "Guidance for industry. Covid-19: developing drugs and biological products for treatment or prevention. Food and Drug Administration, 2020. Available: https://www.fda.gov/media/137926/download. Accessed 3 Oct 2021." }, { "DOI": "10.1093/biomet/80.1.27", "author": "D Firth", "doi-asserted-by": "publisher", "first-page": "27", "journal-title": "Biometrika", "key": "1031_CR15", "unstructured": "Firth D. Bias reduction of maximum likelihood estimates Get access Arrow. Biometrika. 1993;80:27–38.", "volume": "80", "year": "1993" }, { "DOI": "10.1016/S1473-3099(22)00129-3", "author": "DJ Sheward", "doi-asserted-by": "publisher", "first-page": "813", "issue": "6", "journal-title": "Lancet Infect Dis", "key": "1031_CR16", "unstructured": "Sheward DJ, Kim C, Ehling RA, et al. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. Lancet Infect Dis. 2022;22(6):813–20.", "volume": "22", "year": "2022" }, { "DOI": "10.1038/s41591-021-01678-y", "author": "LA VanBlargan", "doi-asserted-by": "publisher", "first-page": "490", "issue": "3", "journal-title": "Nat Med", "key": "1031_CR17", "unstructured": "VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28(3):490–5.", "volume": "28", "year": "2022" } ], "reference-count": 17, "references-count": 17, "relation": {}, "resource": { "primary": { "URL": "https://link.springer.com/10.1007/s40121-024-01031-z" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy" }